Drug intelligence / Profile preview

BMS-986453

Development stage: Phase 2
Lead developer: Bristol Myers Squibb
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

BMS-986453 is an investigational autologous chimeric antigen receptor T-cell (CAR-T) therapy designed to simultaneously target and bind to tumor cells expressing B-cell maturation antigen (BCMA) and/or G protein-coupled receptor class C group 5 member D (GPRC5D). By targeting both BCMA and GPRC5D, the therapy induces selective toxicity in multiple myeloma cells that express either or both antigens. It is being developed for the treatment of relapsed and/or refractory multiple myeloma. The drug is currently in Phase 1 clinical trials[1][2][4][7].

Other names: anti-BCMA/anti-GPRC5D CAR-T cells

Targets

BCMA (B-cell maturation antigen)GPRC5D

Beyond the preview

Go deeper on BMS-986453.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMS-986453.

Explore the full profile